Anne Governor has been selected to provide testimony at a hearing of the US Food and Drug Administration regarding an application from Vertex Pharmaceuticals. Anne is an adult living with CF and is a member of CFFC’s board of directors.

Here is the text of CFRI’s announcement of the FDA hearing:

As reported last week, on May 12, 2015, the Pulmonary-Allergy Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold a hearing to discuss Vertex Pharmaceuticals’ new drug application for approval of the lumacaftor/ivacaftor combination therapy for the treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the F508del mutation.

Sue Landgraf, CFRI’s executive director, hopes to address the committee during oral presentations from the public to advocate for FDA approval of the combination therapy. Many thanks to those of you who have already volunteered to speak at the hearing to educate the committee about the devastating challenges posed by the disease, and the need for this new therapy.

To read the FDA’s announcement of the hearing, click here.